StockTipsArenaBeta

BUY Aurobindo Pharma — Rajesh Satpute

BUYAurobindo Pharma
Aurobindo Pharma share price target & all analyst calls

byRajesh SatputeHorizon: Intraday8 Sept 2026, 9:22 am ISTvia CNBC Awaaz.

Entry₹1,679.3Inferred
Target₹1,700
Total upside +1.23% (call closed)
Stop loss₹1,660-1.15% risk
At expiry₹1,678.48 Sept 2026, 3:05 pm
Expired-0.05%
Follow Rajesh Satpute for new calls(8% target hit, 124 closed calls)Get alertsWatch AUROPHARMA for new buy/sell callsGet alerts

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 8 Sept 2026
2 supporting2 neutral0 opposing
Supports the BUY call (2)

3 advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · adjacent horizon·8 Sept · today

Aurobindo stock gains on generic Advair launch

NewsGoogle News·1 Sept · 6d ago

(opens in new tab)
Neutral / worth noting (2)

Aurobindo Pharma arm Apitoria incorporates Avogent Lifesciences as subsidiary

NewsGoogle News·1 Sept · 6d ago

(opens in new tab)

Aurobindo Pharma Ltd's wholly owned subsidiary, Apitoria Pharma Private Limited, has incorporated a new wholly owned subsidiary named Ávogent Lifesciences Private Limited.

BSE · Company Update·1 Sept · 1w ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Aurobindo Pharma

All analyst calls on Aurobindo Pharma

More from Rajesh Satpute

Every call and its outcome